Oncology Research Today is a free monthly online journal that collates and summarizes the latest research about Oncology, including details on cancer, surgery, chemotherapy, radiotherapy.

Volume 4 (2008), Issue 3 (March)

1. Gender differences in sleep, fatigue, and daytime activity in a pediatric oncology sample receiving dexamethasone.
   J Pediatr Psychol, 33(3): 298-306. [Abstract] [Full-text]
2. Does Timing of Androgen Deprivation Influence Radiation-Induced Toxicity? A Secondary Analysis of Radiation Therapy Oncology Group Protocol 9413.
   Urology. [Abstract] [Full-text]
3. Knowledge and attitudes of Turkish oncology nurses about cancer pain management.
   Pain Manag Nurs, 9(1): 17-25. [Abstract] [Full-text]
4. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, Abonour R, Division of Hematology-Oncology, Indiana University School of Medicine, Indianapolis, IN.
   Urol Oncol, 26(2): 218. [Abstract] [Full-text]
5. Is full bilateral retroperitoneal lymph node dissection always necessary for post-chemotherapy residual tumor? Beck SD, Foster RS, Bihrle R, Donohue JP, Einhorn LH, Department of Urology and Oncology, Indiana University Medical Center, Indianapolis, IN.
   Urol Oncol, 26(2): 218-9. [Abstract] [Full-text]
6. Globalization of the Radiation Therapy Oncology Group: implementation of a model for service expansion and public health improvement.
   J Clin Oncol, 26(7): 1160-6. [Abstract] [Full-text]
7. Developing clinical recommendations for breast, colorectal, and lung cancer adjuvant treatments using the GRADE system: a study from the Programma Ricerca e Innovazione Emilia Romagna Oncology Research Group.
   J Clin Oncol, 26(7): 1033-9. [Abstract] [Full-text]
8. Clinical outcome analysis in "high-risk" versus "low-risk" patients eligible for national surgical adjuvant breast and bowel B-39/radiation therapy oncology group 0413 trial: five-year results.
   Int J Radiat Oncol Biol Phys, 70(4): 970-3. [Abstract] [Full-text]
9. Targeted molecular imaging in oncology: focus on radiation therapy.
   Semin Radiat Oncol, 18(2): 136-48. [Abstract] [Full-text]
10. Proteomics: methodologies and applications in oncology.
    Semin Radiat Oncol, 18(2): 115-25. [Abstract] [Full-text]
11. Using microarray analysis as a prognostic and predictive tool in oncology: focus on breast cancer and normal tissue toxicity.
    Semin Radiat Oncol, 18(2): 105-14. [Abstract] [Full-text]
12. Tissue microarrays in clinical oncology.
    Semin Radiat Oncol, 18(2): 89-97. [Abstract] [Full-text]
13. From cellular to high-throughput predictive assays in radiation oncology: challenges and opportunities.
    Semin Radiat Oncol, 18(2): 75-88. [Abstract] [Full-text]
14. Developing a self-rating measure of patient competence in the context of oncology: a multi-center study.
    Psychooncology. [Abstract] [Full-text]
15. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study.
    Clin Cancer Res, 14(5): 1407-12. [Abstract] [Full-text]
16. The ethics of off-label use of drugs: oncology pharmacy in Italy.
    J Clin Pharm Ther, 33(2): 95-9. [Abstract] [Full-text]
17. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403).
    Br J Cancer, 98(5): 907-14. [Abstract] [Full-text]
18. Spirituality as a core domain in the assessment of quality of life in oncology.
    Psychooncology. [Abstract] [Full-text]
19. Performance of Interleukin-6 and Interleukin-8 serum levels in pediatric oncology patients with neutropenia and fever for the assessment of low-risk.
    BMC Infect Dis, 8(1): 28. [Abstract] [Full-text]
20. Discontinued drugs in 2006: oncology drugs.
    Expert Opin Investig Drugs, 17(3): 269-83. [Abstract] [Full-text]
21. Recommendations on the Use of 18F-FDG PET in Oncology.
    J Nucl Med, 49(3): 480-508. [Abstract] [Full-text]
22. Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897.
    J Clin Oncol, 26(8): 1223-30. [Abstract] [Full-text]
23. Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group.
    Blood, 111(6): 3276-85. [Abstract] [Full-text]
24. Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group.
    Blood, 111(6): 2984-90. [Abstract] [Full-text]
25. Use of complementary and alternative medicine by patients attending a head and neck oncology clinic.
    J Laryngol Otol. [Abstract] [Full-text]
26. Comparison of chemotherapy education and patient preferences in community versus academic gynecology oncology clinics.
    J Oncol Pharm Pract, 14(1): 31-6. [Abstract] [Full-text]
27. Evolving roles of oncology pharmacists in Singapore: a survey on prescribing patterns of antiemetics for chemotherapy induced nausea and vomiting (CINV) at a cancer centre.
    J Oncol Pharm Pract, 14(1): 23-9. [Abstract] [Full-text]
28. Effects on spectrum and susceptibility patterns of isolates causing bloodstream infection by restriction of fluoroquinolone prophylaxis in a hematology-oncology unit.
    Eur J Clin Microbiol Infect Dis, 27(3): 209-16. [Abstract] [Full-text]
29. What constitutes a "clinical trial"?: A survey of oncology professionals.
    Trials, 9: 12. [Abstract] [Full-text]
30. Asians with localized prostate cancer treated with 3-dimensional conformal radiation therapy and adjuvant hormonal therapy: comparing Phoenix and American Society of Therapeutic Radiology and Oncology (ASTRO) definitions in an Asian population.
    Urology, 71(3): 506-10. [Abstract] [Full-text]
31. Conventional and novel PET tracers for imaging in oncology in the era of molecular therapy.
    Cancer Treat Rev, 34(2): 103-121. [Abstract] [Full-text]
32. Haemato-oncology and burnout: an Italian survey.
    Br J Cancer, 98(6): 1046-52. [Abstract] [Full-text]
33. Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial.
    J Clin Oncol, 26(9): 1532-6. [Abstract] [Full-text]
34. A Prospective Study of Risk-Reducing Salpingo-oophorectomy and Longitudinal CA-125 Screening among Women at Increased Genetic Risk of Ovarian Cancer: Design and Baseline Characteristics: A Gynecologic Oncology Group Study.
    Cancer Epidemiol Biomarkers Prev, 17(3): 594-604. [Abstract] [Full-text]
35. Use of chemotherapy at the end of life in a Portuguese oncology center.
    Support Care Cancer, 16(4): 321-7. [Abstract] [Full-text]
36. Evaluation of a tablet PC technology to screen and educate oncology patients.
    Support Care Cancer, 16(4): 371-8. [Abstract] [Full-text]
37. Conducting routine fatigue assessments for use in clinical oncology practice: patient and provider perspectives.
    Support Care Cancer, 16(4): 379-86. [Abstract] [Full-text]
38. Retrospective chart review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology practices: assessment of clinical consequences.
    Support Care Cancer, 16(4): 393-8. [Abstract] [Full-text]
39. An evaluation of amikacin nephrotoxicity in the hematology/oncology population.
    Am J Ther, 15(2): 131-6. [Abstract] [Full-text]
40. An observational study of oncology patients' utilization of breakthrough pain medication.
    J Pain Symptom Manage, 35(4): 406-11. [Abstract] [Full-text]
41. Effect of a nausea expectancy manipulation on chemotherapy-induced nausea: a university of Rochester cancer center community clinical oncology program study.
    J Pain Symptom Manage, 35(4): 381-7. [Abstract] [Full-text]
42. The safety of concurrent administration of opioids via epidural and intravenous routes for postoperative pain in pediatric oncology patients.
    J Pain Symptom Manage, 35(4): 412-9. [Abstract] [Full-text]
43. Assessment of "best practice" treatment patterns for a "radiation oncology community outreach group" engaged in cancer disparities outcomes.
    J Am Coll Radiol, 5(4): 571-8. [Abstract] [Full-text]
44. Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006.
    Arch Intern Med, 168(6): 632-42. [Abstract] [Full-text]
45. Adaptation of the OODA Loop to reduce postoperative nausea and vomiting in a high-risk outpatient oncology population.
    J Perianesth Nurs, 23(2): 78-86. [Abstract] [Full-text]
46. Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy.
    Ann Oncol, 19(4): 787-92. [Abstract] [Full-text]
47. Low-grade mucosa-associated lymphoid tissue lymphoma: a retrospective analysis of 97 patients by the Hellenic Cooperative Oncology Group (HeCOG).
    Ann Oncol, 19(4): 780-6. [Abstract] [Full-text]
48. Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG).
    Ann Oncol, 19(4): 801-6. [Abstract] [Full-text]
49. Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626.
    J Clin Oncol, 26(10): 1650-6. [Abstract] [Full-text]
50. Molecular pathology-translating research into clinical practice: an expanding frontier in surgical oncology.
    Surg Oncol Clin N Am, 17(2): 303-21. [Abstract] [Full-text]
51. Development and psychometric evaluation of the Basic Documentation for Psycho-Oncology, a tool for standardized assessment of cancer patients.
    J Psychosom Res, 64(4): 373-81. [Abstract] [Full-text]
52. Japanese Structure Survey of Radiation Oncology in 2005 Based on Institutional Stratification of Patterns of Care Study.
    Int J Radiat Oncol Biol Phys. [Abstract] [Full-text]
53. ACR Appropriateness Criteria on Resectable Rectal Cancer Expert Panel on Radiation Oncology-Rectal/Anal Cancer.
    Int J Radiat Oncol Biol Phys, 70(5): 1427-30. [Abstract] [Full-text]

© 2005-2008 Oncology Research Today. All Rights Reserved.